Divi's Laboratories Ltd.
DIVISLABHealthcare filings
We hold this company’s filings and have not read the financial statements out of them yet. Every filing on record is listed under filings, and each one opens.
Earnings calls
25 transcript(s)/analyst meet(s) served; 7 document(s) on file are not transcripts (cover letters, duplicates, unresolved) and are excluded. Speaker attribution is shown only where the segmenter attributes ≥ 95% of sentences to management or analysts (0 of 25 documents here); elsewhere sentences render unattributed.
| Kind | Date | Period | Served | Attribution rate |
|---|---|---|---|---|
| TRANSCRIPT | 20220526 | 2022-03-31 | yes | |
| COVER_LETTER | 20220812 | 2022-06-30 | no | |
| TRANSCRIPT | 20220817 | 2022-06-30 | yes | |
| COVER_LETTER | 20221107 | 2022-09-30 | no | |
| TRANSCRIPT | 20221114 | 2022-09-30 | yes | |
| TRANSCRIPT | 20230208 | 2022-12-31 | yes | |
| COVER_LETTER | 20230520 | 2023-03-31 | no | |
| TRANSCRIPT | 20230525 | 2023-03-31 | yes | |
| COVER_LETTER | 20230814 | 2023-06-30 | no | |
| TRANSCRIPT | 20230819 | 2023-06-30 | yes | |
| COVER_LETTER | 20231106 | 2023-09-30 | no | |
| TRANSCRIPT | 20231111 | 2023-09-30 | yes | |
| COVER_LETTER | 20240210 | 2023-12-31 | no | |
| TRANSCRIPT | 20240216 | 2023-12-31 | yes | |
| COVER_LETTER | 20240525 | 2024-03-31 | no | |
| TRANSCRIPT | 20240530 | 2024-03-31 | yes | |
| TRANSCRIPT | 20240808 | 2024-06-30 | yes | |
| TRANSCRIPT | 20241115 | 2024-09-30 | yes | |
| TRANSCRIPT | 20250207 | 2024-12-31 | yes | |
| TRANSCRIPT | 20250523 | 2025-03-31 | yes | |
| TRANSCRIPT | 20250812 | 2025-06-30 | yes | |
| TRANSCRIPT | 20251112 | 2025-09-30 | yes | |
| TRANSCRIPT | 20260214 | 2025-12-31 | yes | |
| TRANSCRIPT | 20260529 | 2026-03-31 | yes | |
| TRANSCRIPT | 20260806 | 2026-06-30 | yes |
DIVISLAB
files the standard Schedule III statements. Every figure below opens to the filing it was read from; where a figure is not shown, the reason is printed in its place.
Identity
| Statement division | general |
| Scope served | consolidated |
| Panels on this page | 4 |
Market
No split, bonus or consolidation is on record for this company inside the period this price series covers, so the closes need no adjustment.
| Last close | 9,602.00 |
| 52-week range | 5689.5 – 9624.0 |
| Return 1M | 9.81% |
| Return 3M | 43.03% |
| Return 1Y | 60.46% |
| Return 3Y | 157.53% |
| Return 5Y | 87.96% |
| Market capitalisation | not shown — we could not confirm it |
| Shares outstanding | not shown — we could not confirm it |
| P/E | not shown — we could not confirm it |
| P/B | not shown — we could not confirm it |
| EV/EBITDA | not shown — we could not confirm it |
Latest quarter filed — period ending 2026-06-30
In INR crore except per-share figures. `period_id` is the period the filing names for the number; the date beside each cell is when it was filed.
| Revenue from operations | 3,080.00 |
| Other income | 64.00 |
| Total income | 3,144.00 |
| Cost of materials consumed | 1,503.00 |
| Purchases of stock-in-trade | 0.00 |
| Changes in inventories | -517.00 |
| Employee benefit expense | 408.00 |
| Finance costs | 6.00 |
Ownership — 2026-06-30, and the change from 2026-03-31
| Holder | Per cent | Change |
|---|---|---|
| promoter and promoter group | 0.52 | 0.00 |
| institutions foreign | 0.20 | -0.00 |
| institutions domestic | 0.19 | 0.00 |
| mutual funds | 0.14 | 0.00 |
| public | 0.48 | 0.00 |
Documents on file
| Class | Most recent | On file |
|---|---|---|
| COVER_LETTER | 2024-03-31 | 7 |
| TRANSCRIPT | 2026-06-30 | 18 |
Financial statements
Filed results, consolidated, in INR crore except per-share figures. Every figure opens to the filing it was read from. Quarterly and annual columns are the periods the filing itself names, never a document date.
Quarterly results, as filed
| Line | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 1,855.00 | 1,708.00 | 1,951.00 | 1,778.00 | 1,909.00 | 1,855.00 | 2,303.00 | 2,118.00 | 2,338.00 | 2,319.00 | 2,585.00 | 2,410.00 | 2,715.00 | 2,604.00 | 2,831.00 | 3,080.00 |
| Other income | 80.00 | 114.00 | 66.00 | 81.00 | 86.00 | 95.00 | 79.00 | 79.00 | 106.00 | 82.00 | 86.00 | 119.00 | 145.00 | 88.00 | 155.00 | 64.00 |
| Total income | 1,935.00 | 1,822.00 | 2,017.00 | 1,859.00 | 1,995.00 | 1,950.00 | 2,382.00 | 2,197.00 | 2,444.00 | 2,401.00 | 2,671.00 | 2,529.00 | 2,860.00 | 2,692.00 | 2,986.00 | 3,144.00 |
| Cost of materials consumed | 817.00 | 604.00 | 808.00 | 829.00 | 711.00 | 794.00 | 898.00 | 893.00 | 976.00 | 1,021.00 | 931.00 | 1,010.00 | 937.00 | 1,217.00 | 1,214.00 | 1,503.00 |
| Purchases of stock-in-trade | 6.00 | 12.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in inventories | -148.00 | 123.00 | 19.00 | -141.00 | 99.00 | -65.00 | -2.00 | -40.00 | -7.00 | -99.00 | 50.00 | -54.00 | 136.00 | -272.00 | -95.00 | -517.00 |
| Employee benefit expense | 232.00 | 239.00 | 258.00 | 263.00 | 266.00 | 268.00 | 297.00 | 292.00 | 304.00 | 297.00 | 350.00 | 340.00 | 354.00 | 367.00 | 381.00 | 408.00 |
| Finance costs | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 | 2.00 | 0.00 | 1.00 | 0.00 | 1.00 | 3.00 | 8.00 | 6.00 | 6.00 | 6.00 |
| Depreciation and amortisation | 86.00 | 87.00 | 87.00 | 93.00 | 95.00 | 95.00 | 95.00 | 97.00 | 99.00 | 99.00 | 107.00 | 112.00 | 113.00 | 118.00 | 120.00 | 133.00 |
| Other expenses | 327.00 | 321.00 | 378.00 | 323.00 | 354.00 | 369.00 | 373.00 | 351.00 | 349.00 | 357.00 | 368.00 | 385.00 | 400.00 | 402.00 | 397.00 | 431.00 |
| Total expenses | 1,319.00 | 1,386.00 | 1,550.00 | 1,367.00 | 1,526.00 | 1,461.00 | 1,669.00 | 1,593.00 | 1,722.00 | 1,675.00 | 1,807.00 | 1,796.00 | 1,948.00 | 1,838.00 | 2,023.00 | 1,964.00 |
| Profit before exceptional items and tax | 615.00 | 436.00 | 466.00 | 492.00 | 469.00 | 489.00 | 713.00 | 604.00 | 722.00 | 726.00 | 864.00 | 733.00 | 912.00 | 854.00 | 963.00 | 1,180.00 |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -74.00 | 0.00 | 0.00 |
| Profit before tax | 615.00 | 436.00 | 466.00 | 492.00 | 469.00 | 489.00 | 713.00 | 604.00 | 722.00 | 726.00 | 864.00 | 733.00 | 912.00 | 780.00 | 963.00 | 1,180.00 |
| Current tax | 95.00 | 107.00 | 102.00 | 125.00 | 107.00 | 122.00 | 160.00 | 179.00 | 218.00 | 174.00 | 228.00 | 191.00 | 220.00 | 208.00 | 249.00 | 291.00 |
| Deferred tax | 27.00 | 22.00 | 43.00 | 11.00 | 14.00 | 9.00 | 15.00 | -5.00 | -6.00 | -37.00 | -26.00 | -3.00 | 3.00 | -11.00 | -37.00 | -13.00 |
| Tax expense | 122.00 | 129.00 | 146.00 | 136.00 | 121.00 | 131.00 | 175.00 | 174.00 | 212.00 | 137.00 | 202.00 | 188.00 | 223.00 | 197.00 | 212.00 | 278.00 |
| Profit for the period | 494.00 | 307.00 | 321.00 | 356.00 | 348.00 | 358.00 | 538.00 | 430.00 | 510.00 | 589.00 | 662.00 | 545.00 | 689.00 | 583.00 | 751.00 | 902.00 |
| Profit attributable to owners | 494.00 | 307.00 | 321.00 | — | 348.00 | 358.00 | 538.00 | 430.00 | 510.00 | 589.00 | 662.00 | 545.00 | 689.00 | 583.00 | 751.00 | 902.00 |
| Profit attributable to non-controlling interests | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other comprehensive income | 3.00 | 3.00 | 1.00 | 1.00 | 1.00 | 5.00 | -7.00 | 1.00 | 1.00 | 1.00 | 0.00 | 3.00 | 3.00 | 16.00 | -1.00 | 2.00 |
| Total comprehensive income | 497.00 | 310.00 | 322.00 | 357.00 | 349.00 | 363.00 | 531.00 | 431.00 | 511.00 | 590.00 | 662.00 | 548.00 | 692.00 | 599.00 | 750.00 | 904.00 |
| Earnings per share, basic | 18.60 | 11.56 | 12.09 | 13.41 | 13.11 | 13.50 | 20.25 | 16.20 | 19.20 | 22.20 | 24.93 | 20.49 | 25.97 | 21.98 | 28.31 | 33.95 |
| Earnings per share, diluted | 18.60 | 11.56 | 12.09 | 13.41 | 13.11 | 13.50 | 20.25 | 16.20 | 19.20 | 22.20 | 24.93 | 20.49 | 25.97 | 21.98 | 28.31 | 33.95 |
Annual results, as filed
| Line | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2026-03-31 |
|---|---|---|---|---|---|---|---|
| Revenue from operations | 5,394.00 | 6,969.00 | 8,960.00 | 7,768.00 | 7,845.00 | 9,360.00 | 10,560.00 |
| Other income | 190.00 | 63.00 | 114.00 | 345.00 | 339.00 | 352.00 | 507.00 |
| Total income | 5,584.00 | 7,032.00 | 9,074.00 | 8,112.00 | 8,184.00 | 9,712.00 | 11,067.00 |
| Cost of materials consumed | 2,198.00 | 2,397.00 | 3,477.00 | 3,008.00 | 3,232.00 | 3,821.00 | 4,378.00 |
| Purchases of stock-in-trade | 16.00 | 5.00 | 14.00 | 22.00 | 6.00 | 0.00 | 0.00 |
| Changes in inventories | -106.00 | -79.00 | -524.00 | 23.00 | -109.00 | -96.00 | -285.00 |
| Employee benefit expense | 621.00 | 826.00 | 946.00 | 975.00 | 1,094.00 | 1,243.00 | 1,442.00 |
| Finance costs | 6.00 | 1.00 | 1.00 | 1.00 | 3.00 | 2.00 | 23.00 |
| Depreciation and amortisation | 186.00 | 256.00 | 312.00 | 343.00 | 378.00 | 402.00 | 463.00 |
| Other expenses | 843.00 | 960.00 | 1,165.00 | 1,371.00 | 1,417.00 | 1,424.00 | 1,584.00 |
| Total expenses | 3,765.00 | 4,366.00 | 5,390.00 | 5,744.00 | 6,021.00 | 6,796.00 | 7,605.00 |
| Profit before exceptional items and tax | 1,819.00 | 2,666.00 | 3,684.00 | 2,369.00 | 2,163.00 | 2,916.00 | 3,462.00 |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -74.00 |
| Profit before tax | 1,819.00 | 2,666.00 | 3,684.00 | 2,369.00 | 2,163.00 | 2,916.00 | 3,388.00 |
| Current tax | 393.00 | 616.00 | 644.00 | 439.00 | 514.00 | 799.00 | 868.00 |
| Deferred tax | 50.00 | 65.00 | 79.00 | 106.00 | 49.00 | -74.00 | -48.00 |
| Tax expense | 443.00 | 682.00 | 723.00 | 545.00 | 563.00 | 725.00 | 820.00 |
| Profit for the period | 1,377.00 | 1,984.00 | 2,960.00 | 1,823.00 | 1,600.00 | 2,191.00 | 2,568.00 |
| Profit attributable to owners | — | 1,984.00 | 2,960.00 | 1,823.00 | 1,600.00 | 2,191.00 | 2,568.00 |
| Profit attributable to non-controlling interests | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other comprehensive income | 0.00 | 0.00 | 4.00 | 12.00 | 0.00 | 3.00 | 21.00 |
| Total comprehensive income | 1,377.00 | 1,985.00 | 2,965.00 | 1,835.00 | 1,600.00 | 2,194.00 | 2,589.00 |
| Earnings per share, basic | 51.85 | 74.75 | 111.52 | 68.69 | 60.27 | 82.53 | 96.75 |
| Earnings per share, diluted | 51.85 | 74.75 | 111.52 | 68.69 | 60.27 | 82.53 | 96.75 |
Balance sheet, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 13,518.00 | 14,439.00 | 14,283.00 | 15,470.00 | 15,586.00 | 16,932.00 | 18,151.00 | 20,033.00 |
| Non-current assets | 5,088.00 | 5,127.00 | 5,401.00 | 5,795.00 | 6,245.00 | 6,851.00 | 8,308.00 | 8,937.00 |
| Current assets | 8,430.00 | 9,312.00 | 8,882.00 | 9,675.00 | 9,341.00 | 10,081.00 | 9,843.00 | 11,096.00 |
| Property, plant and equipment | 4,322.00 | 4,714.00 | 4,648.00 | 4,733.00 | 4,652.00 | 5,437.00 | 5,672.00 | 6,515.00 |
| Capital work-in-progress | 542.00 | 212.00 | 496.00 | 778.00 | 1,316.00 | 1,022.00 | 2,030.00 | 2,113.00 |
| Goodwill | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other intangible assets | 10.00 | 8.00 | 6.00 | 6.00 | 6.00 | 4.00 | 4.00 | 13.00 |
| Inventories | 2,970.00 | 3,000.00 | 2,969.00 | 3,184.00 | 3,145.00 | 3,236.00 | 3,433.00 | 3,954.00 |
| Trade receivables | 1,840.00 | 1,793.00 | 1,858.00 | 2,156.00 | 2,181.00 | 2,731.00 | 2,614.00 | 2,984.00 |
| Cash and cash equivalents | 250.00 | 170.00 | 35.00 | 363.00 | 38.00 | 415.00 | 83.00 | 128.00 |
| Total equity and liabilities | 13,518.00 | 14,439.00 | 14,283.00 | 15,470.00 | 15,586.00 | 16,932.00 | 18,151.00 | 20,033.00 |
| Equity | 12,135.00 | 12,767.00 | 12,677.00 | 13,571.00 | 13,717.00 | 14,969.00 | 15,413.00 | 16,761.00 |
| Equity share capital | 53.00 | 53.00 | 53.00 | 53.00 | 53.00 | 53.00 | 53.00 | 53.00 |
| Other equity | 12,082.00 | 12,714.00 | 12,624.00 | 13,518.00 | 13,664.00 | 14,916.00 | 15,360.00 | 16,708.00 |
| Total liabilities | 1,384.00 | 1,672.00 | 1,606.00 | 1,899.00 | 1,869.00 | 1,963.00 | 2,738.00 | 3,272.00 |
| Non-current liabilities | 469.00 | 571.00 | 595.00 | 621.00 | 578.00 | 511.00 | 1,010.00 | 1,229.00 |
| Current liabilities | 914.00 | 1,101.00 | 1,011.00 | 1,278.00 | 1,291.00 | 1,452.00 | 1,728.00 | 2,043.00 |
| Borrowings, non-current | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Borrowings, current | 0.00 | 0.00 | 2.00 | 0.00 | 5.00 | 2.00 | 89.00 | 0.00 |
| Trade payables | 675.00 | 763.00 | 788.00 | 824.00 | 855.00 | 910.00 | 1,040.00 | 1,211.00 |
Cash flow, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Net cash from operating activities | 1,486.00 | 2,460.00 | 539.00 | 1,261.00 | 926.00 | 1,653.00 | 1,645.00 | 2,738.00 |
| Net cash from investing activities | -1,653.00 | -2,708.00 | 122.00 | -269.00 | -459.00 | -804.00 | -1,261.00 | -2,219.00 |
| Net cash from financing activities | -797.00 | -797.00 | -798.00 | -799.00 | -792.00 | -799.00 | -720.00 | -804.00 |
| Purchase of property, plant and equipment | 247.00 | 473.00 | 494.00 | 1,003.00 | 664.00 | 1,438.00 | 1,544.00 | 2,520.00 |
| Net increase in cash | -965.00 | -1,045.00 | -137.00 | 193.00 | -325.00 | 50.00 | -336.00 | -285.00 |
| con:CFO.BEFORE_TAX | 1,761.00 | 2,932.00 | 780.00 | 1,637.00 | 1,298.00 | 2,477.00 | 2,012.00 | 3,600.00 |
| con:INTEREST_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INTEREST_PAID.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:DIVIDENDS_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:TAX_PAID.OPERATING | 276.00 | 473.00 | 241.00 | 376.00 | 372.00 | 824.00 | 367.00 | 862.00 |
| con:CF_OTHER.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_PURCHASED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:PPE_DISPOSALS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00 | 3.00 |
| con:CF_INVESTING.SUBSIDIARIES_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.SUBSIDIARIES_ACQUIRED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_ACQUIRED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Who owns it
The shareholding pattern filed with the exchange every quarter, as a series. Percentages are of total shares. Each figure names the filing it was read from and the date it was filed.
| Holder | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter and promoter group | 51.94 | 51.93 | 51.93 | 51.92 | 51.92 | 51.90 | 51.89 | 51.89 | 51.89 | 51.89 | 0.52 | 0.52 | 0.52 | 0.52 |
| Domestic institutions | 21.07 | 21.23 | 21.75 | 21.88 | 22.21 | 21.77 | 21.06 | 20.54 | 20.71 | 19.05 | 0.20 | 0.19 | 0.19 | 0.19 |
| Mutual funds | — | — | — | — | — | — | — | — | — | 13.31 | 0.14 | 0.14 | 0.13 | 0.14 |
| Insurance companies | 6.78 | 6.91 | 7.17 | 7.21 | 7.24 | 8.03 | 8.56 | 7.66 | 7.23 | 5.10 | 0.05 | 0.05 | 0.05 | 0.04 |
| Foreign institutions | 14.67 | 14.70 | 14.60 | 14.86 | 14.68 | 16.16 | 17.25 | 17.99 | 18.01 | 19.74 | 0.19 | 0.20 | 0.20 | 0.20 |
| Government | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Public | 48.06 | 48.07 | 48.07 | 48.08 | 48.08 | 48.10 | 48.11 | 48.11 | 48.11 | 48.11 | 0.48 | 0.48 | 0.48 | 0.48 |
| Non-institutional | 12.31 | 12.14 | 11.72 | 11.33 | 11.19 | 10.18 | 9.80 | 9.58 | 9.39 | 9.32 | 0.09 | 0.09 | 0.09 | 0.09 |
| Shares outstanding | 265468580 | 265468580 | 265468580 | 265468580 | 265468580 | 265468580 | 265468580 | 265468580 | 265468580 | 265468580 | 265468580 | 265468580 | 265468580 | 265468580 |
Related parties
Transactions with related parties as disclosed to the exchange for the period ending 2024-09-30, by counterparty, largest first. Amounts are as filed. Each row names the filing and the date it was filed.
| Counterparty | Relationship | Type | Amount in the period | Transactions |
|---|---|---|---|---|
| Divi's Laboratories Europe AG | Subsidiary Company | Sale of goods or services | 1,127,000,000.00 | 2 |
| Divis Laboratories (USA) Inc | Subsidiary Company | Sale of goods or services | 892,800,000.00 | 2 |
| Dr. Murali. K. Divi | Key Management Personnel | Remuneration | 398,700,000.00 | 1 |
| Mr. N.V. Ramana | Key Management Personnel | Remuneration | 204,900,000.00 | 1 |
| Sri Lakshmi Constructions | Entities in which Key Management P | Any other transaction, Purchase of goods or services | 149,600,000.00 | 2 |
| Dr. Kiran S. Divi | Key Management Personnel | Remuneration | 139,900,000.00 | 1 |
| Ms. Nilima Prasad Divi | Key Management Personnel | Remuneration | 139,500,000.00 | 1 |
| Divi’s Properties Private Limited | Entities in which Key Management P | Any other transaction | 59,600,000.00 | 2 |
| Divi'S Foundation For Gifted Children | Other Related Party | Any other transaction | 36,000,000.00 | 1 |
| Mr. L. Kishore Babu | Key Management Personnel | Remuneration | 19,000,000.00 | 1 |
| Dr. Devendra Rao Sureddi | Key Management Personnel | Remuneration | 15,300,000.00 | 1 |
| Mr. L. Ramesh Babu | Relative of Key Management Personn | Remuneration | 13,900,000.00 | 1 |
| Mr. M. Satish Choudhury | Key Management Personnel | Remuneration | 2,200,000.00 | 1 |
| Mr Swaroop Krishna Sureddi | Relative of Key Management Personn | Remuneration | 1,900,000.00 | 1 |
| Dr. Ramesh B. V. Nimmagadda | Non-Executive Director | Any other transaction | 1,700,000.00 | 1 |
What management said
Every earnings call we hold for this company, read in full. Prepared remarks are separated from the question-and-answer session and every paragraph names who said it and on which page. These are management’s own words, not filed figures.
| Date | Quarter | Who spoke | |
|---|---|---|---|
| 2026-08-06 | Q1FY27 | LABORATORIES LIMITED | Read the call |
| 2026-05-29 | Q4FY26 | LABORATORIES LIMITED | Read the call |
| 2026-02-14 | Q3FY26 | LABORATORIES LIMITED | Read the call |
| 2025-11-12 | Q2FY26 | LABORATORIES LIMITED | Read the call |
| 2025-08-12 | Q1FY26 | LABORATORIES LIMITED | Read the call |
| 2025-05-23 | Q4FY25 | (FINANCE AND ACCOUNTS) | Read the call |
| 2025-02-07 | Q3FY25 | DIVI'S LABORATORIES LIMITED, LIMITED | Read the call |
| 2024-11-15 | Q2FY25 | (COMMERCIAL), EXECUTIVE OFFICER | Read the call |
| 2024-08-08 | Q1FY25 | (COMMERCIAL), CHIEF EXECUTIVE OFFICER | Read the call |
| 2024-05-30 | Q4FY24 | (COMMERCIAL), EXECUTIVE OFFICER | Read the call |
| 2024-02-16 | Q3FY24 | (COMMERCIAL), CHIEF EXECUTIVE OFFICER | Read the call |
| 2023-11-11 | Q2FY24 | (COMMERCIAL) | Read the call |
| 2023-08-19 | Q1FY24 | (COMMERCIAL), DIVI’S LABORATORIES LIMITED, DIVI’S LABORATORIES LIMITED, LABORATORIES LIMIT | Read the call |
| 2023-05-25 | Q4FY23 | DIVI'S LABORATORIES LIMITED, LABORATORIES LIMITED | Read the call |
| 2023-02-08 | Q3FY23 | DIVI'S LABORATORIES LIMITED, LABORATORIES LIMITED | Read the call |
| 2022-11-14 | Q2FY23 | LIMITED | Read the call |
| 2022-08-17 | Q1FY23 | (FINANCE AND ACCOUNTS) | Read the call |
| 2022-05-26 | FYFY22 | (COMMERCIAL), DIVI’S LABORATORIES LIMITED, DIVI’S LABORATORIES LIMITED, LABORATORIES LIMIT | Read the call |
Some earlier announcements under this heading are covering letters only — no transcript was attached.
What they said about it, quarter by quarter
| Topic | Q3FY23 | Q3FY24 | Q3FY25 | Q3FY26 | Q4FY23 | Q4FY24 | Q4FY25 | Q4FY26 |
|---|---|---|---|---|---|---|---|---|
| Capex | The INR 1,000 crores is the capex we want to do going ahead? | The GLP-1 protected amino acids where you are under qualification with various customers, would this require subsequent CAPEX and then the commercial … | Previously, we thought from the new plant in the Kakinada will be fully operational by another 6 months or 8 months, and the order flow looks like qui… | Kiran, my first question is on the dedicated capex that we had announced in 2024. | Construction activity on the 500 acres of land is progressing well and capex of INR 1,200 crores to INR 1,500 crores for Phase 1 development is in the… | On the Custom Synthesis business, the long-term agreement that we announced, the separate capex, couldn't this have been done in Kakinada given that c… | Several of the large pharma companies in the US have announced large capital expenditure to kind of reshore the manufacturing. | And another question, sir, since the massive GLP-led capex that is going on worldwide, so if you can give your plan for -- capex plan for the next yea… |
| Capital allocation | — | — | — | — | — | I meant to ask whether this would require another land acquisition, so from that perspective? | — | — |
| Costs | Raw material procurement and availability have been stabilized and the material prices have slightly softened compared to the last quarter. | We don’t look at it as a threat because we start from basic raw material. | On the procurement front, raw material prices remained stable throughout the third quarter with no major disruptions in the availability. | We are seeing this more from chemicals and the raw material point of view. | In fact efficiencies have gone up, we see the trend of prices even going down for the raw materials. | The price erosion has been there, but we did get an advantage from the reduction in the raw material prices as well and certain other variable costs a… | These efforts are designed to mitigate delays and ensure continuity of raw material inflows, thereby minimizing any operational impact. | So regards to the raw material availability, you have elaborated for the quarter, but could you share -- or is it fair to believe that the worst is be… |
| Debt and cash | — | — | — | — | — | The second question in is on cash flow from operations for full year fiscal '24 and '23, roughly similar PBTs, like ₹100 crores difference here or the… | So is this like a normalization on the working capital side? | — |
| Demand | And I just foresee the new products, new pipelines, new chemistries, what else can be introduced, like the vapor- phased chemistry, continuous flow ch… | What is the potential opportunity further that is there with the potential pipeline that we might be addressing those? | With a strong pipeline, expanding capabilities and commitment to innovation, we are confident in our ability to sustain long-term growth and create va… | And once Unit 3 started, phase-wise, we have been emptying Unit 1 and 2 as and when there is demand, where the blocks get empty, and we are using them… | With increased opportunities and demand for generic APIs in segments such as contrast media, sartans and products about to go off patent; we foresee m… | Several companies did not finish their pipeline. | And we have several products in the pipeline, some are going through R&D phases, some are in pilot scales right now. | See, particularly, I wanted to know about the methanol because we are one of the leading consumer of methanol in the country and almost entire of this… |
| Guidance | And we anticipate in the coming quarters, it should be better. | If you could kind of give us an outlook for the generic piece specifically and also the elaboration on the comments you said that once the patents exp… | In our generic business, despite the ongoing price pressures affecting the industry, we have maintained stability, while we expect this pressure to gr… | When should we expect commissioning of that capacity and probably inspections or whatever regulatory approvals are required? | So would you like to give us some guidance on the growth for FY '24 and on the sartan that you mentioned, are we the exclusive supplier there? | So we expect going ahead pricing erosion to be there. | Looking ahead, we expect this proactive approach combined with continued price and supply stability to keep our procurement environment favorable over… | And also it would be great if you can share your margin outlook for FY27, given the kind of difficult scenario, how challenging and what is the kind o… |
| Margin | First on the gross margin thing -- so the kind of product mix that is there. | The first question is on the margin front. | So, considering all that, also considering Kakinada would have a little operational additional expenses, we don't see a massive dip in the entire marg… | There are some products which would have higher margins, some products with lower margin. | Sir, would like to understand in terms of raw material pricing trajectory where we stand based having backward integration in place as well and so is … | Sir, my second question, if I say, is about the margin profile. | So, how should we see this the generic growth, whether it is driven by the price rise and whether that has contributed to the overall margin scenario … | The second question I have on the margin side. |
| People | — | But sequentially, can you help us with how the utilizations have improved? | But could you give some sense what is the kind of utilization in the Unit 1 and 2 that we will be operating at? | So what is the capacity that we would be having or at what utilization that we would be operating at? | So, no loans, it's only better utilization of reserves which are in the form of fixed deposits. | — | — | — |
| Pricing | This growth is primarily driven by volume despite pricing pressures. | I think Dr. Kiran at the start talked about generic pricing pressure. | February 03, 2025 pricing pressure, the number is not looking great. | So while the raw materials are now stable, I presume -- and as you highlighted, the pricing are also relatively competitive enough. | It is the raw materials, which were procured at higher prices, which we had to consume them and we have to charge the pricing based on the inventory w… | My first question, Kiran, you mentioned in your opening remarks that the pricing environment for generics continues to be under pressure. | This quarter we witnessed relative stability in raw material pricing, which is an encouraging sign given the fluctuations seen in the previous quarter… | But yes, there has been pricing pressures. |
| Revenue growth | So just about the revenue growth visibility. | So, for near-term margins, we should be focused more on cost efficiency, etc., like what was discussed earlier, that should be driving the margins and… | The other one is the easy base effect for us in terms of Y-o-Y growth probably reduces going forward, right, if I were to just assume you do the same … | — | — | Maybe if you can answer this even top down, like what should be the growth outlook or the top line growth overall, maybe you're not going to share wha… | Would it be right to say that going forward as we clock a double-digit revenue growth, like as a percentage of sales this is the kind of inventory lev… | So I have first question on our constant currency top line growth, which has been around 6%, as you mentioned in the opening remarks. |